In Brief: E-Z-EM/Abbott
This article was originally published in The Gray Sheet
Executive Summary
E-Z-EM/Abbott: E-Z-EM's Enteric Products, Inc. subsidiary reaches marketing agreement with Abbott Laboratories covering serum and whole-blood versions of physician's office tests (co-developed by EPI and SmithKline Diagnostics) for the detection of H. Pylori. Under the agreement, Abbott will market the tests, which are manufactured by SKD, under the name FlexPack HP in China, India, other Asian countries, Eastern Europe, and parts of the Middle East and Africa. SKD also markets the tests under the name FlexSure HP in the U.S. and other "selected" regions. In return, EPI will receive revenue from: product sales directly to Abbott; royalties from product sales to Abbott by SKD and from SKD to distributors and end-users; and sales of EPI's HM-CAP antigen to SKD for use in the tests...
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.